Pfizer Elaborates On Celebrex Safety Theory: Molecule Is “Unique”
Executive Summary
Celebrex can be differentiated from other COX-2 inhibitors based on relative rates of association with hypertensive cell retention, Pfizer Worldwide Development President Joe Feczko told analysts Nov. 30 in Groton, Conn
You may also be interested in...
Vioxx Cardiovascular Risk Is Unique To Molecule, Pfizer And Novartis Tell FDA
The cardiovascular safety signal observed in Merck's Vioxx may be caused by the formation of potentially toxic rofecoxib metabolites, Pfizer states in its briefing documents for FDA's upcoming review of COX-2 inhibitors
Vioxx Cardiovascular Risk Is Unique To Molecule, Pfizer And Novartis Tell FDA
The cardiovascular safety signal observed in Merck's Vioxx may be caused by the formation of potentially toxic rofecoxib metabolites, Pfizer states in its briefing documents for FDA's upcoming review of COX-2 inhibitors
Bextra Meta-Analysis Affirms Safety Profile, Pfizer Tells Physicians
A meta-analysis of Bextra (valdecoxib) clinical trials in osteoarthritis and rheumatoid arthritis show the agent has a lower incidence of myocardial infarctions compared to traditional NSAIDs, Pfizer maintains in Dec. 2 "medical information letters.